Article
A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern rheumatology care.
All News
Article
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Article
Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested.
Article
Dr. Jack Cush reviews the journal articles and regulatory announcements from this past week on RheumNow, including: two crystals in one joint, twice the cryptococcus risk in JAKs; Myositis and Scleroderma; and Sjögren’s plus early damage = >> 2 fold risk lymphoma. Double trouble week on the RheumNow podcast.
Dr. John Cush
Tweet
Exagen studies 192 established RA pts (383 controls) for Abs: CCP2, RF IgA, RF IgM, PAD4 (IgA, IgG). RA signif assoc w/ CCP2+ (OR 110), RF (>7), PAD4 (3.5-5.9). In CCP neg - only PAD4 IgG (2.87) & RF (2.2) assoc w/ RA, w/ only small Dx gain (ΔAUC 0.02–0.04). https://t.co/isf7aMf24O
Jiha Lee
Tweet
Same molecule, different route, different persistence: golimumab IV persisted 4.44 yrs vs 2.07 for SC in biologic-naive RA (n=9,464, Korean claims). Is it the route, or differenntial out of pocket cost, or supervised dosing and better adherence? P#240 #APLAR26 @RheumNow
Jiha Lee
Tweet
Older adults with RA on JAKi: filgotinib may carry a lower zoster risk than others. Is it JAK1 selectivity? UPA (available in the US) is also selective. Dose, zoster vaccination status and a mixed comparator group may matter. Day 3 Abst Session 7 #APLAR26 @RheumNow https://t.co/5ri4shAHnV
Jiha Lee
Tweet
Raychaudhuri (day 2 plenary): Reconceptualizing cells as continuous states, not discrete types. In RA synovium, AMP defined six inflammation patterns (CTAPs) with key cell states, e.g. Tph in T+B. Do CTAPs respond to different targets? #APLAR26 @RheumNow https://t.co/jIosTqv5qZ
Dr. John Cush
Tweet
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/xTlr5lrwUz
Peter Nash
Tweet
T cell clone in AxSpA Trvb9 & Trav 21 B27 pos pts - t cell engager developed
@RheumNow #APLAR2026 https://t.co/Jt7XBu3Kok
Peter Nash
Tweet
number of naive-like CAR-T infused associates with prolonged survival but highly variable
APLAR Seoul 2026 #CAR-T #Rheum Now
Peter Nash
Tweet
Georg Schett : cure prime goal of therapy! remission off all treatment ,
APLAR Seoul 2026 #CART #RheumNow https://t.co/kygOGdxUSe
Peter Nash
Tweet
“Complex to manage” in SLE not for biologics
APLAR Seoul 2026 Nikpour #SLE #RheumNow https://t.co/4qeRGEVijs
Dr. John Cush
Tweet
Artiva has stopped development of its AlloNK (allogeneic NK cell therapy) after 2 reported deaths in their phase II RCT in #RA and other autoimmune conditions. Artiva has suspended its phase III trial with AlloNK. https://t.co/mLR6xciRfB https://t.co/mv2m8rhst6
Dr. John Cush
Tweet
Mark your calendar: RheumNow is covering ACR Convergence 2026, beginning November 7th!
Follow along for clinical trial highlights, expert perspectives, daily faculty recaps, livestreams and more.
Visit https://t.co/ofGKCCNQnE for the latest coverage.
#ACR26 #Rheumatology https://t.co/5p5UxMLu51
Dr. John Cush
Tweet
JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/jQQGzhAm7c
Dr. John Cush
Tweet
Treat-to-Target has Excellent 10-Year Outcomes in RA
Most patients with RA whose initial treatment used a stringent treat-to-target strategy in a clinical trial were in remission 10 years later, with only modest radiographic progression over that time, researchers said. https://t.co/aWQgQAsoSI
Dr. John Cush
Tweet
Cryptococcus is rare, but twice as likely with JAK inhibitors. Retrospective TriNetX analysis of RA pts (>30k/grp) starting JAKi vs TNFi; JAKi vs non-TNFi; & TNFi vs non-TNF. Crypto seen in <0.2% in all groups; but signif higher HR for JAKi (HR 2.2 & 2.15) https://t.co/1J4SjcqF8u
Dr. John Cush
Tweet
Biologic safety. Vasculitis mimics. What to do with seropositive arthralgia.
RheumNow Live 2027 tackles the decisions you face in clinic.
Jan. 30–31 | Onsite + virtual
Registration NOW OPEN.
Early Bird Pricing through 12/15/2026.
https://t.co/zYYC2350tE https://t.co/mPI1o7sEcx
Dr. John Cush
Tweet
Joint Disease in SLE Reconsidered
A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may https://t.co/M5m6TMZr3x
